The global whole genome and exome sequencing market is projected to reach $7,467.6 million by 2033 from $1,873.8 million in 2023, growing at a CAGR of 15.13% during the forecast period 2024-2033.
The Europe automated sample preparation market was valued at $381.3 million in 2023 and is expected to reach $925.1 million by 2033, growing at a CAGR of 9.27% between 2023 and 2033.
The global hematologic malignancies testing market was valued at $3,546.3 million in 2023 and is expected to reach $13,509.5 million by 2033, growing at a CAGR of 14.09% during the forecast period 2024-2033.
The global liquid biopsy market was valued at $4,072.6 million in 2023 and is expected to reach $20,224.7 million by 2033, growing at a CAGR of 16.83% during the forecast period 2024-2033.
The global hereditary genetic testing market is projected to reach $81.95 billion by 2033 from $24.78 billion in 2023, growing at a CAGR of 12.73% during the forecast period 2024-2033.
Need reports on an on-going basis? Do consider our annual subscription
The global metagenomics market was valued at $1,808.0 million in 2023 and is expected to reach $9,286.1 million by 2033, growing at a CAGR of 17.90% between 2024 and 2033.
The global genome sequencing market was valued at $7.56 billion in 2023 and is expected to reach $30.23 billion by 2033, growing at a CAGR of 15.18% between 2024 and 2033.
The Asia-Pacific genomic cancer panel and profiling market is expected to reach $4.78 billion by 2033 from $1.56 billion in 2023.
The Europe MRD testing market is projected to reach $1,744.0 million by 2033 from $424.0 million in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033.
The Europe DNA/RNA sample extraction and isolation market was valued at $629.0 million in 2023 and is expected to reach $1,236.2 million by 2033, growing at a CAGR of 6.99% between 2023 and 2033.
The global targeted sequencing market was valued at $3,479.8 million in 2023 and is expected to reach $10,987.4 million by 2033, growing at a CAGR of 12.28% between 2024 and 2033.
The global precision medicine software market was valued at $1,824.9 million in 2023 and is expected to reach $5,696.3 million by 2033, growing at a CAGR of 12.13% between 2024 and 2033.
The global microarray analysis market was valued at $5,357.9 million in 2023 and is expected to reach $10,112.4 million by 2033, growing at a CAGR of 6.56% during the forecast period 2023-2033.
The global companion diagnostics market was valued at $3,762.0 million in 2023 and is expected to reach $12,498.7 million by 2033, growing at a CAGR of 12.76% between 2023 and 2033.
The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033.
The global colorectal cancer screening and diagnostics market was valued at $38,540.7 million in 2023 and is expected to reach $48,710.9 million by 2033, growing at a CAGR of 2.37% during the forecast period 2023-2033.
The global nucleic acid sample preparation market is projected to reach $5,615.9 million by 2033 from $2,922.8 million in 2023, growing at a CAGR of 6.75% during the forecast period 2023-2033.
The MRD testing market was valued at $1.47 billion in 2022 and is expected to reach $6.67 billion by 2033, growing at a CAGR of 14.81% between 2023 and 2033.
The Asia-Pacific next-generation IVD market was valued at $21.43 billion in 2023 and is expected to reach $42.35 billion by 2033, growing at a CAGR of 7.05% between 2023 and 2033.
The Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market is projected to reach $1,779.4 Million by 2032 from $554.3 Million in 2023, growing at a CAGR of 13.84% during the forecast period 2023-2032.
In 2023, the Asia-Pacific organ transplant diagnostics market was valued at $1.25 billion and is expected to reach $3.45 billion by 2033, with a CAGR of 10.73% during the forecast period 2023-2033.
The global automated sample preparation market was valued at $1,431.9 million in 2023 and is expected to reach $3,730.5 million by 2033, growing at a CAGR of 10.05% between 2023 and 2033.
The Asia-Pacific MRD testing market is projected to reach $1.33 billion by 2033 from $0.30 billion in 2023, growing at a CAGR of 16.06% during the forecast period 2023-2033.
The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach $2,545.6 million by 2033 from $534.3 million in 2023 at a CAGR of 16.90% during the forecast period 2023-2033.
In 2023, the Europe functional genomics market was valued at $3.01 billion, and it is expected to reach $10.69 billion by 2033.
The Asia-Pacific single-cell multi-omics market is projected to reach $1.85 billion by 2033 from $0.30 billion in 2023, growing at a CAGR of 20.00% during the forecast period 2023-2033.
The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033.
The Asia-Pacific gene editing technologies market was valued at $0.49 billion in 2023 and is anticipated to reach $5.05 billion by 2032, witnessing a CAGR of 29.64% during the forecast period 2023-2032.
The global DNA methylation detection technology market was valued at $2.80 billion in 2023 and is expected to reach $12.32 billion by 2033, growing at a CAGR of 15.96% between 2023 and 2033.
The Europe multicancer screening market is projected to reach $2.09 billion by 2032 from $0.55 billion in 2023, growing at a CAGR of 15.93% during the forecast period 2023-2032.
The global clinical biomarkers market was valued at $24.80 billion in 2023 and is expected to reach $53.20 billion by 2033, growing at a CAGR of 7.93% between 2023 and 2033.
The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033.
The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $426.3 million in 2023 and is expected to reach $2,233.6 million by 2033.
The Asia-Pacific NGS data storage market is projected to reach $1,284.3 million by 2033 from $207.5 million in 2023, growing at a CAGR of 19.99% during the forecast period 2023-2033.
As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033.
The Asia-Pacific rare disease genetic testing market was valued at $0.51 billion in 2022 and is expected to reach $2.40 billion by 2033, witnessing a CAGR of 15.25% during the forecast period 2023-2033.
The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033.
The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032.
The report offer a comprehensive overview of the microcarriers market, highlighting key trends, growth drivers, challenges, and opportunities shaping this dynamic industry.
The Asia-Pacific laboratory automation market was valued at $1.17 billion in 2022 and is expected to reach $3.69 billion by the end of 2033, registering a CAGR of 11.03% during the forecast period 2023-2033.
The immunoassay plays a pivotal role in diagnostics and therapeutic applications, encompassing a wide range of techniques such as ELISA, western blotting, radioimmunoassay, and rapid tests.
ELISpot and FluoroSpot Assay Market play a crucial role in immunological research and diagnostics, and this report projects the market landscape on a global scale.
The global genomic cancer panel and profiling market is expected to reach $26.59 billion by 2033 from $9.90 billion in 2022.
The report highlights the transformative impact of biologic therapies on individuals suffering from chronic inflammatory diseases, showcasing how these treatments have not only reduced dependency on health and welfare systems but also improved patients' physical function, enabling them to live more independently.
As of 2022, the Asia-Pacific multicancer screening market was valued at $0.27 billion and is expected to attain a value of $1.40 billion by 2032.
The Europe nucleic acid sample preparation market is projected to reach $3,356.7 million by 2032 from $1,307.4 million in 2022, growing at a CAGR of 9.89% during the forecast period 2022-2032.
In 2022, the India emerging infectious disease diagnostics market was valued at $339.1 million and is expected to grow at a CAGR of 10.29% during the forecast period 2023-2033 to register a value of $982.7 million in 2033.
The market is expected to grow at a CAGR of 7.07% during the forecast period 2023-2033 and attain a value of $4.79 billion by 2033.
The global laboratory automation market was valued at $9.17 billion in 2022 and is anticipated to reach $24.84 billion by 2033, witnessing a CAGR of 9.57% during the forecast period 2023-2033.
The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated to reach $897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033.
The global rare disease genetic testing market was valued at $4.11 billion in 2022 and is anticipated to reach $16.69 billion by 2033, witnessing a CAGR of 13.69% during the forecast period 2023-2033.
The next-generation IVD market was valued at $86.21 billion in 2022 and is expected to reach $152.62 billion by 2033, growing at a CAGR of 5.41% between 2023 and 2033.
The global emerging infectious disease diagnostics market was valued at $19.56 billion in 2022 and is expected to reach $37.21 billion by 2033, growing at a CAGR of 6.19% between 2023 and 2033.
The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is anticipated to reach $455.53 million by 2032, witnessing a CAGR of 19.73% during the forecast period 2023-2032.
The global acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033.
The global cell and gene therapy manufacturing QC market was valued at $1.95 billion in 2022 and is anticipated to reach $10.65 billion by 2033, witnessing a CAGR of 16.85% during the forecast period 2023-2033.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033.
The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033.
The global single-cell multi-omics market is projected to reach $7.72 billion by 2033 from $1.43 billion in 2022, growing at a CAGR of 17.27% during the forecast period 2023-2033.
The global NGS data storage market is projected to reach $6.96 billion by 2033 from $1.13 billion in 2022, growing at a CAGR of 18.02% during the forecast period 2023-2033.
In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.
The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032.
A monthly review of how COVID-19 is impacting the diagnostics, therapeutics, and vaccines market. Overall, more than 225 treatment options were reported in April 2023.
In 2022, the global organ transplant diagnostics market was valued at $4.03 billion and is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033.
The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032.
The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is anticipated to reach $2,370.7 million by 2027, witnessing a CAGR of 17.56% during the forecast period 2022-2027.
The U.S. DTC wellness testing market is projected to reach $4,946.3 million by 2032 from $878.9 million in 2022, at a CAGR of 18.86% during the forecast period 2022-2032.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global nucleic acid sample preparation market is projected to reach $11,200.5 million by 2032 from $4,213.0 million in 2022, growing at a CAGR of 10.27% during the forecast period 2022-2032.
The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030.
The global NGS informatics market was valued at $1,380.0 million in 2021 and is projected to reach $6,715.0 million by the end of 2032.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
In 2021, the global prostate cancer testing market was valued at $5,246.9 million, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
The U.S. hereditary genetic testing market was valued at $7.57 billion in 2021 and is forecasted to reach $29.28 billion by 2032.
The global flow cytometry in oncology and immunology market was valued at $1,653.2 million in 2021 and is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032.
The global laboratory informatics market was valued at $4,341.2 million in 2021 and is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
In 2021, the global NGS kits market was valued at $4,553.6 million, and it is expected to reach $26,057.4 million by 2032, growing at a CAGR of 17.27% during the forecast period 2022-2032.
In 2021, the global NGS library preparation automation market was valued at $1,273.2 million, and it is expected to reach $3,803.3 million by 2029, growing at a CAGR of 14.85% during the forecast period 2022-2029.
The global cell-free RNA isolation and extraction kits market is projected to reach $140.7 million by 2032 from $30.2 million in 2021, growing at a CAGR of 14.98% during the forecast period 2022-2032.
The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at a CAGR value of 12.24% during the forecast period 2022-2032.
The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032.
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032.
The global human identification market is projected to reach $6,435.6 million by 2032 from $1,385.8 million in 2021, at a CAGR of 14.77% during the forecast period 2022-2032.
The global NGS oncology market is projected to reach $51,783.0 million in 2032 from 14,828.6 million in 2021, witnessing a CAGR of 12.04% during the forecast period 2022-2032.
The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032.
The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%.
The U.S. solid tumor testing market is projected to reach $18,287.6 million by 2032 from $9,498.8 million in 2021, at a CAGR of 6.19% during the forecast period 2022-2032.
The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031.
The global liquid biopsy market is projected to reach $19,066.0 million by 2032 from $2,508.2 million in 2021 at a CAGR of 19.83% during the forecast period 2022-2032.
In 2021, the Middle East liquid biopsy market was valued at $43.7 million, and it is expected to reach $175.2 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.
The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031.
In 2021, the Middle East precision medicine market was valued at $3,942.6 million, and it is expected to reach $8,620.0 million by 2032, growing at a CAGR of 7.37% during the forecast period 2022-2032.
In 2020, the global single cell bioinformatics software and services market was valued at $205.2 million, and it is expected to reach $634.8 million by 2031, growing at a CAGR of 10.89% during the forecast period 2021-2031.
The Europe infectious disease diagnostics market is projected to reach $7,900.4 million by 2031 from $1,394.3 million in 2020, at a CAGR of 16.48% during the forecast period 2021-2031.
The single cell RNA sequencing market is anticipated to reach a value of $2,931.3 million in 2031 from $386.7 million in 2020, witnessing a CAGR of 17.08% during the forecast period 2021-2031.
The report contains the analysis of variables such as recent trends, technological advancements, and international level initiatives across the globe influencing the adoption of acellular therapy.
The global gene cloning services market was valued at $1,983.6 million in 2020 and is expected to reach $11,524.4 million by 2031, growing at a CAGR of 17.29% during the forecast period 2021-2031.
The report constitutes a strategical information and implementation for the plasma medicine market.
The global capillary electrophoresis market was valued at $318.3 million in 2020 and is expected to reach $586.9 million by 2031, growing at a CAGR of 5.66% during the forecast period 2021-2031.
In 2020, the global next-generation gynecological cancer diagnostics market was valued at $1,976.5 million, which is expected to reach $5,657.7 million by 2031, growing at a CAGR of 10.07% during the forecast period 2021-2031.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
The global precision cardiology market is projected to reach $3,584.6 million by 2031 from $956.6 million in 2020, at a CAGR of 12.90% during the forecast period 2021-2031.
The in-silico drug discovery market is projected to reach $10,409.9 million by 2031 from $1,619.6 million in 2020, at a CAGR of 18.47% in the forecast period of 2021-2031.
The neoantigen cancer vaccine market is projected to reach $1,988.5 million by 2031 from $35.5 million in 2024, at a compound annual growth rate (CAGR) of 77.73%.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031.
The global NGS sample preparation market is projected to reach $3,279.3 million by 2026, growing from $1,468.9 million in 2020, at a CAGR of 14.24% during the forecast period 2021-2026.
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031.
The global carrier screening market is projected to reach $4,479.0 million by 2031, growing from $1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.
In 2020, the global epigenetics market was valued at $2,434.6 million, and it is expected to reach $14,311.1 million by 2031, growing at a CAGR of 17.11% during the forecast period 2021-2031.
In 2020, the global cancer microbiome sequencing market was valued at $155.5 million, and it is expected to reach $1,216.2 million by 2031, growing at a CAGR of 20.01% during the forecast period 2021-2031.
The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.
The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from $10,914.6 million in 2020, at a CAGR of 7.38% during the forecast period 2021-2031.
The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031.
The global transcriptomics market is projected to reach $33.68 billion by 2031 from $4.47 billion in 2020, at a CAGR of 20.11% during the forecast period 2021-2031.
The global organ transplant diagnostics market is projected to reach $9,663.0 million by 2031, growing from $3,100.3 million in 2020, at a CAGR of 10.92% during the forecast period 2021-2031.
The global gel documentation systems market is projected to reach $411.1 million by 2030 from $275.4 million in 2020, at a CAGR of 4.04% during the forecast period 2021-2030.
The global liquid handling systems market was valued to be $3,210.2 million in 2020 and is expected to reach $7,128.1 million by 2031, witnessing a CAGR of 7.43% during the forecast period 2021-2031.
The global direct-to-consumer genetic testing market accounted for $1,155.9 million in 2020 and is expected to be $6,604.5 million by 2031.
The global non-invasive liquid biopsy market is projected to reach $9,470.3 million by 2031, growing from $1,096.9 million in 2020, at a CAGR of 20.38% during the forecast period 2021-2031.
The global industrial microbiological QC market is predicted to grow at a CAGR of 5.69% over the forecast period of 2021-2031.
The global nutrigenomics market is set to witness a CAGR of 17.26% during the forecast period 2021-2031.
The nucleic acid isolation and purification market is projected to reach $5,010.3 million by 2031 from $2,304.7 million in 2020, at a CAGR of 7.20%.
The global long-read sequencing market is projected to reach $3,305.5 million by 2030 from $504.7 million in 2020, at a CAGR of 21.15% during the forecast period 2021-2030.
The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031.
The global market for mRNA vaccines and therapeutics for COVID-19 vaccines is predicted to decline at a CAGR of 13.50% over the forecast period of 2021-2025.
The global reproductive genetics market is predicted to grow at a CAGR of 12.38% over the forecast period 2021-2030.
The global oncolytic virus therapies market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.
The global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030.
The global solid tumor testing market is projected to reach $40,660.6 million by 2030 from $22,504.1 million in 2020, at a CAGR of 6.09% during the forecast period 2020-2030.
The global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026.
The global market for somatic genetic testing is predicted to grow at a CAGR of 9.30% over the forecast period of 2020-2030.
The global rare disease diagnostics market has been currently witnessing a rapid growth and is expected to continue to grow at a CAGR of 8.57% during the forecast period, 2020-2030.
The global market for cell and gene therapy manufacturing QC is predicted to grow at a CAGR of 22.80% over the forecast period of 2020-2030.
The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.
The global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.
The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030.
The global market for Genomic data analysis and interpretation is predicted to grow at a CAGR of 10.21% over the forecast period of 2020-2030.
The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period of 2020-2025.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
The spatial genomics and transcriptomics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 23.20% during the forecast period of 2020-2030.
The global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021.
The global non-oncology precision medicine market was valued at $41.1 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.03% and reach a value of $129.96 billion in 2030.
The population sequencing market is projected to reach $64,047.6 million by 2030 from $21,730.4 million in 2020, at a CAGR of 11.41% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030.
The global precision medicine market is set to witness a CAGR of 11.13% during the period between 2020 and 2030.
The global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025.
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030.
The global pediatric genetic testing market is expected to grow at a double-digit compound annual growth rate of 14.30% in the forecast period 2020-2030.
The global skin microbiome modulators market was valued at $541.1 million in 2019 and is anticipated to grow over $2,971.6 million by 2030.
The global genetic counseling market was valued at $972.2 million in 2019 and is anticipated to grow over $4,079.3 million by 2030.
The global DNA methylation market is predicted to grow at a CAGR of 15.70% over the forecast period of 2020-2030.
The global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.
The global market for infectious disease rapid diagnostics is predicted to grow at a CAGR of 12.36% over the forecast period of 2020-2025.
The U.S. solid tumor testing market is projected to reach $15,396.4 million by 2030 from $8,179.7 million in 2019, at a CAGR of 5.91% during the forecast period 2020-2030.
The global market for whole genome and exome sequencing is predicted to grow at a CAGR of 26.94% over the forecast period of 2019-2029.
The global companion diagnostics market to grow at a significant CAGR of 12.45% during the forecast period, 2020-2030.
The nucleic acid isolation and purification industry analysis by BIS Research projects the market to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029.
Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029.
The Global Human Microbiome Sequencing Market Report by BIS Research projects the market to grow at a significant CAGR of 19.44% during the forecast period, 2019-2029.
The RNA sequencing industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.21% during the forecast period, 2019-2028.
The U.S. hematologic malignancies market analysis by BIS Research projects the market to grow at a significant CAGR of 14.60% during the forecast period, 2019-2025.
The minimally invasive biopsy technologies market industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2030.
The single cell sequencing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029.
The in-silico drug discovery industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029.
The global neoantigen cancer vaccine market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030.
The global microfluidics market to grow at a significant CAGR of 13.73% during the forecast period, 2019-2029.
The global recombinant cell culture supplements market to grow at a significant CAGR of 12.93% during the forecast period, 2019-2029.
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025.
The global molecular forensics market has been currently witnessing a rapid growth and is expected to continue to grow with a CAGR of 9.09% during the forecast period, 2019-2029.
Human Microbiome Therapeutics Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 33.00% during the forecast period 2019-2029.
The NGS sample preparation industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.54% during the forecast period, 2019-2025.
The global blockchain in genomic market analysis by BIS Research projects the market to grow at a significant CAGR of 66.42% during the forecast period, 2019-2029.
The global molecular diagnostic point of care industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029.
The global stem cell therapy market to grow at a significant CAGR of 27.99% during the forecast period, 2019-2029.
The global NGS based monitoring and diagnostic test market to grow at a significant CAGR of 18.08% during the forecast period, 2019-2028.
The aim of the population genomic initiatives implemented across the globe is to develop the biobank of genomic datasets facilitating the understanding of interaction between the gene and the phenotypic expression.
The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025.
The China Precision Medicine Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2029.
The Global Oligonucleotide Synthesis Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 11.02% during the forecast period from 2019 to 2029.
The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.
The global single cell multi-omics industry analysis by BIS Research projects that the market was valued at $1.83 billion in 2018 and is anticipated to generate a value of $5.32 billion by 2025.
The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028.
The global direct-to-consumer market was valued at approximately $824.1 million in 2018 and is anticipated to reach $6,364.5 million by 2028.
In 2018, the global next-generation sequencing market was valued at $4.93 billion and is anticipated to grow at a CAGR of 13.18% in the forecast period 2019-2024.
The Latin America cell culture market has been witnessing a steady growth. The market is expected to continue to grow with a single digit CAGR of 6.20% during the forecast period, 2018-2025.
The global industrial microbiological QC market is expected to continue to grow with a single digit CAGR of 6.22% during the forecast period, 2019-2028.
The Latin America cell analysis market is anticipated to reach $1,566.7 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025.
The Latin America liquid biopsy market is anticipated to reach $70.9 million by 2025, witnessing a CAGR of 10.29% in the forecast period 2019-2025.
The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028.
The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028.
The global molecular diagnostics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 10.89% during the forecast period, 2018-2028.
The global recombinant cell culture supplements market was valued $230.5 million in 2017 and is anticipated to reach $788.6 million by 2028.
The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025.
As of 2019, the global NGS informatics and clinical genomics market was estimated to be approximately $957.0 million and is expected to reach a value of an estimated $5,016.0 million by the end of 2028.
The global liquid biopsy market is anticipated to reach $2.94 billion by 2028, witnessing a CAGR of 14.45% in the forecast period 2018-2028.
The global CDx market is expected to continue to grow with a double digit CAGR of 21.38% during the forecast period, 2018-2025.
In 2017, the global precision medicine market accounted for $48.9 billion, which is expected to reach ~$70 billion by 2020 with effective implementation of several novel technologies.
The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is anticipated to reach $98.24 billion by 2025.
The global cell free DNA isolation and extraction market was valued at $81.7 million in 2016, and is anticipated to reach $442.8 million by 2026.
The global POCT market was estimated at $13.87 billion in 2017 and is estimated to grow over $23.92 billion by 2026.
The global laboratory automation systems market was estimated at $5.05 billion in 2016 and is anticipated to reach $9.55 billion by 2026.
The global regenerative medicines market is expected to reach $50.55 billion by 2025.
The global precision medicine market was dominated by the oncology segment in 2016. The oncology market is expected to grow with a CAGR of 10.4% from 2017 to 2026. The rise in the number of cancer cases has significantly increased the global economic burden and is estimated to be approximately $4 trillion in 2025.
(Focus on Product Type, Technology, Application, Country Analysis, Market Share Analysis, Funding Scenario, Trend Analysis, and Competitive Landscape)
The global liquid biopsy market is anticipated to grow over $4,434 million by 2025. With the growing prominence for non-invasive diagnostic procedures, the global liquid biopsy market is expected to register an impressive double digit growth rate in the forecast period 2016-2025.
The global cancer imaging systems is expected to reach $11 billion by 2025.
North America was the largest market for NIPT in 2016 in terms of revenue and volume. The region is expected to retain its leadership position throughout the forecast period as major players in the NIPT market are based in the U.S. (the largest shareholder in North America).
The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2016 to 2023 and reach a figure of $6.34 billion by 2023. The advancements in technology, adoption of biomarker tests, and increasing cancer incidence rate are some of the major driving factors for this market. The global emerging cancer diagnostics market has been classified on the basis of test type, appli
The pharmacovigilance market is expected to reach a market size of $8.23 billion by 2022. Stringent compliance with drug safety regulations and increasing incidents of ADRs are acting as key drivers for the growth of this market.
The global prenatal testing market is growing at a CAGR of 28.85% from 2016 to 2022 and is estimated to grow over $7.2 billion by 2022. Prenatal tests are classified into two main categories viz. Screening and Diagnostics. Both screening and diagnostics have witnessed an exponential growth in procuring treatments for disorders which increased in the past two decades.
Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.
Prenatal Testing and Newborn Screening is one of the most modernized trends in the healthcare industry which has shown a tremendous level of progress in the last few years. The growth of prenatal and newborn genetic testing market is attributed primarily to a rapid increase in genetic disorders/abnormalities, increase in fetal mortality, and advancement of healthcare technologies. The global prena
Precision medicine is becoming one of the most modernized trends in the healthcare industry showing an incredible growth in the recent years. According to the report put forward by the market research experts of BIS Research, the global precision medicine market is expected to grow over $88 billion by 2022 at an estimated CAGR of 12.60% from 2015 to 2022.
The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033.
The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032.
Protein sequencing is a critical technique in life sciences that determines the order of amino acids in a protein molecule.
Cardiac marker tests offer valuable information to healthcare providers, facilitating rapid diagnosis and risk stratification of cardiac events.
Incubator Systems Market explores market based on segmentations such as by technology, by end user, and by product type, the impact of macroeconomic factors market growth
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global nucleic acid sample preparation market is projected to reach $11,200.5 million by 2032 from $4,213.0 million in 2022, growing at a CAGR of 10.27% during the forecast period 2022-2032.
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032.
The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032.
The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%.
The global liquid biopsy market is projected to reach $19,066.0 million by 2032 from $2,508.2 million in 2021 at a CAGR of 19.83% during the forecast period 2022-2032.
The global organ transplant diagnostics market is projected to reach $9,663.0 million by 2031, growing from $3,100.3 million in 2020, at a CAGR of 10.92% during the forecast period 2021-2031.
The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031.
The global recombinant cell culture supplements market was valued $230.5 million in 2017 and is anticipated to reach $788.6 million by 2028.
The global molecular diagnostics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 10.89% during the forecast period, 2018-2028.
The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028.
The global industrial microbiological QC market is expected to continue to grow with a single digit CAGR of 6.22% during the forecast period, 2019-2028.
The global direct-to-consumer market was valued at approximately $824.1 million in 2018 and is anticipated to reach $6,364.5 million by 2028.
The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028.
The global single cell multi-omics industry analysis by BIS Research projects that the market was valued at $1.83 billion in 2018 and is anticipated to generate a value of $5.32 billion by 2025.
The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.
The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025.
The NGS sample preparation industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.54% during the forecast period, 2019-2025.
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025.
The global recombinant cell culture supplements market to grow at a significant CAGR of 12.93% during the forecast period, 2019-2029.
The global neoantigen cancer vaccine market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030.
The in-silico drug discovery industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029.
The nucleic acid isolation and purification industry analysis by BIS Research projects the market to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029.
Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029.
The global market for whole genome and exome sequencing is predicted to grow at a CAGR of 26.94% over the forecast period of 2019-2029.
The U.S. solid tumor testing market is projected to reach $15,396.4 million by 2030 from $8,179.7 million in 2019, at a CAGR of 5.91% during the forecast period 2020-2030.
The global companion diagnostics market to grow at a significant CAGR of 12.45% during the forecast period, 2020-2030.
The global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.
The market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030.
The global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025.
The global liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period of 2020-2025.
The global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.
The global rare disease diagnostics market has been currently witnessing a rapid growth and is expected to continue to grow at a CAGR of 8.57% during the forecast period, 2020-2030.
The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031.
The global organ transplant diagnostics market is projected to reach $9,663.0 million by 2031, growing from $3,100.3 million in 2020, at a CAGR of 10.92% during the forecast period 2021-2031.
The global liquid biopsy market is projected to reach $19,066.0 million by 2032 from $2,508.2 million in 2021 at a CAGR of 19.83% during the forecast period 2022-2032.
The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%.
The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032.
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032.
The global nucleic acid sample preparation market is projected to reach $11,200.5 million by 2032 from $4,213.0 million in 2022, growing at a CAGR of 10.27% during the forecast period 2022-2032.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
Precision Medicine
Precision Medicine Market & Industry Overview
Precision medicine is an innovative approach that tailor's medical treatment and prevention to an individual's unique characteristics, such as genetics, environment, and lifestyle. This market focuses on developing targeted therapies, diagnostics, and interventions, enabling personalized and effective patient care. With advancements in genomics, data analytics, and molecular diagnostics, precision medicine is poised to revolutionize healthcare by improving treatment efficacy, reducing adverse effects, and ultimately enhancing patient outcomes.
BIS Research has groomed a team of dynamic technology consultants with a sheer focus on the precision medicine market. The team is predominantly acknowledged for eminent business decision support catering to the business needs of emerging companies in the healthcare industry.
The precision medicine industry has understood the importance of integrating new technologies such as applied sciences, precision diagnostics, precision therapeutics, and digital health and information technology.
Applied Sciences: This has been sub-segmented as genomics, pharmacogenomics, and other applied sciences.
Genomics: In genomics, BIS Research reports cover polymerase chain reaction (PCR), next-generation sequencing (NGS), genome editing, and an array of technologies, where instruments, reagents, and consumables have been considered.
Pharmacogenomics: BIS Research report considers both products (PCR, microarray, sequencers) and services (genotyping, SNP identification, pharmacogenetic testing).
Other Applied Sciences: BIS Research report considers proteomics, metabolomics, biomarker sciences, and system biology.
Precision Diagnostics: This includes tests used to identify and specify DNA or RNA sequencing, which is associated with the specific disease, hybridization, PCR, and array analysis to analyze genetic materials, proteins, fragments, and other various molecular and cellular targets. It also includes sequences that are not related to any specific disease, such as single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others.
Molecular Diagnostics: This includes instruments and consumables for companion diagnostic, non-invasive prenatal testing (NIPT), liquid biopsy, and other molecular diagnostics (MDx virology, MDx bacteriology, MDx hospital-acquired infection, MDx genetic testing, MDx oncology (excluding CDx, LB), MDx human leukocyte antigen (HLA), and MDx blood donor screening).
Medical Imaging: This includes instruments such as magnetic resonance imaging (MRI) and computed tomography (CT).
Precision Therapeutics: This includes technologies that are used for the development of gene therapies, cell therapies, and risk prediction in clinical trials.
Digital Health and Information Technology: This is focused on computational infrastructures for data storage, technology platforms, data privacy, and protection. This includes clinical decision support systems (CDSS), big data analytics, IT infrastructure, genomics informatics, in-silico informatics, and mobile health.
Hundreds of businesses in this industry have trusted BIS Research’s insight reports to make important decisions and grow in the market. From a regional perspective, we are witnessing the early adoption of deep technologies in the precision medicine market in countries such as the U.S., the U.K., China, Germany, Japan, Canada, France, South Korea, and others.
Our customer base expands across several sections, including small enterprises, medium-scale operations, Fortune 50+ companies, as well as government organizations, venture capitalists, and deemed universities.
BIS Research’s Precision Medicine segment offers intelligence reports with solutions aimed at helping healthcare businesses improve operational efficiency and patient outcomes and reduce costs. With the help of its exhaustive research projects, the company has developed a comprehensive and unique country-level database of healthcare infrastructure. BIS Research is keeping a close watch on the latest precision medicine industry developments. In case you do not find a report of your choice in the above-mentioned list, please feel free to contact us to customize a report for you.
I would like to extend our appreciation for your support in finalizing the report according to our precise needs and prerequisites. I am also impressed by the timely completion of all aspects of dealing with us as your esteemed client. I look forward to continue our professional relations in the future.
Manager-Strategy & Business DevelopmentICL Industrial Products
“I found the content quite interesting and insightful. It has provided us with some important information”
Strategic Insights COE ManagerJapan Tobacco International
I appreciate the extra effort that team BIS took to cater to our specific requirements, moreover, their response time and adaptability is at par with my expectation.
CEO & ChairmanTEKNA Plasma Systems
“BIS research has been a great support to our strategic investigation in the field of thermoplastic composite. BIS did manage to bring together a clear picture on a global level, supported by examples and references and they delivered an accurate evaluation of the current market size and potential in the coming years in line with our expectations. I warmly recommend them.”
VPFuture Business and Innovation